89bio Inc

89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded in January 2018 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.

89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease

Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution compared to placebo in a Phase 2b clinical trial. The drug, pegozafermin, also demonstrated fibrosis improvement, without worsening of NASH.

89bio's stock rallies 48% on new NASH data

- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) -

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH.

89Bio: A Promising NASH Innovator

Ardelyx

Cabaletta Bio

iShares Genomics Immunology and Healthcare ETF

Meihua International Medical Technologies Co

Verona Pharma

Biotech is all over the 52-week high leaderboard

Is This the Most Lucrative Way to Play AI?

The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

89bio is a clinical-stage company focused on the treatment of liver and cardio-metabolic diseases. The company's lead candidate, pegozafermin, shows strong efficacy and favorable tolerability in treating non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

89bio: Lead Candidate Shows Strong Efficacy In NASH And SHTG Trials

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status –

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

Coty

Mueller Water

OneSpaWorld Holdings Limited

Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.

4 Best Breakout Stocks to Buy for Superb Returns

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 PM ET.

89bio to Participate in the SVB Securities Global Biopharma Conference

Fintel reports that Orbimed Advisors Llc has filed a 13D/A form with the SEC disclosing ownership of 1.50MM shares of 89bio Inc (ETNB).

Orbimed Advisors Reduces Position in 89bio

89BIO (ETNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

89bio Provides Business Update and Outlook for 2023

ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action.

89Bio: Let's Not Give Up Already

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids –

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023-

89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously reported -

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022

SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17, 2022 at 11:30 AM ET.

89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET.

89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

-Results featured in a late-breaking oral presentation-

89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022

ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that.

89bio: NASH Data Next Year May Change Things For The Better

219 total patients enrolled; topline data expected in the first quarter of 2023 219 total patients enrolled; topline data expected in the first quarter of 2023

89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 -

News for 89bio Inc Stock (ETNB)